| Year |
Citation |
Score |
| 2020 |
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). PMID 32888407 DOI: 10.1016/S0140-6736(20)31366-0 |
0.336 |
|
| 2020 |
Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Advances. 4: 2227-2235. PMID 32442301 DOI: 10.1182/Bloodadvances.2020001554 |
0.389 |
|
| 2020 |
Iyengar M, Purev E, Haverkos B, Smith C, Pollyea DA, Gutman JA. Incidence of Pulmonary GVHD Is Increased and Incidence of Late Infection and Pulmonary Embolism Is Comparable Comparing Adult MRD Versus Cord Transplant Patients Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.180 |
0.307 |
|
| 2019 |
Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Advances. 3: 2911-2919. PMID 31648312 DOI: 10.1182/Bloodadvances.2019000243 |
0.309 |
|
| 2019 |
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Experimental Hematology. PMID 31136781 DOI: 10.1016/J.Exphem.2019.05.002 |
0.345 |
|
| 2019 |
Gaikwad H, Wang G, Smith WJ, Alexander KL, D'Alessandro A, Zhang W, Purev E, Simberg D. Clickable Methyltetrazine-Indocarbocyanine Lipids: A Multicolor Tool Kit for Efficient Modifications of Cell Membranes. Bioconjugate Chemistry. PMID 31050882 DOI: 10.1021/Acs.Bioconjchem.9B00202 |
0.332 |
|
| 2019 |
Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, ... ... Purev E, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390 |
0.324 |
|
| 2019 |
Gutman JA, Sharma P, Purev E, Smith C, Winters A, Hammes A, Loken MR, Pollyea DA. Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy Blood. 134: 4615-4615. DOI: 10.1182/Blood-2019-129150 |
0.328 |
|
| 2019 |
Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, et al. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood. 134: 2638-2638. DOI: 10.1182/Blood-2019-122120 |
0.319 |
|
| 2019 |
Lum J, Purev E, Gutman JA, Melander K, Beckham JD, Abidi MZ. Successful Reduced Intensity Stem Cell Transplant in a Patient with Myeloproliferative Neoplasm/Myelodysplastic (MPN/MDS) Overlap Syndrome Diagnosed with West Nile Virus Encephalitis. Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.598 |
0.315 |
|
| 2018 |
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. PMID 30420752 DOI: 10.1038/S41591-018-0233-1 |
0.348 |
|
| 2018 |
Zhang W, Jordan KR, Schulte B, Purev E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Design, Development and Therapy. 12: 3343-3356. PMID 30323566 DOI: 10.2147/Dddt.S175113 |
0.324 |
|
| 2018 |
Sharma P, King GT, Shinde SS, Purev E, Jimeno A. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas. Drugs of Today (Barcelona, Spain : 1998). 54: 187-198. PMID 29771253 DOI: 10.1358/Dot.2018.54.3.2776625 |
0.352 |
|
| 2018 |
Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared to Transplantation Following Standard Reduced-Intensity Conditioning: a Retrospective Cohort Comparison. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29684565 DOI: 10.1016/J.Bbmt.2018.04.019 |
0.38 |
|
| 2018 |
Brayer JB, Sallman DA, Kerre T, Poire X, Havelange V, Lewalle P, Wang ES, Selleslag D, Anguille S, Beguin Y, Purev E, Al-Homsi A, Dekker D, Breman E, Sotiropoulou PA, et al. Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia Blood. 132: 1398-1398. DOI: 10.1182/Blood-2018-99-114747 |
0.349 |
|
| 2018 |
Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant Blood. 132: 2138-2138. DOI: 10.1182/Blood-2018-99-110834 |
0.342 |
|
| 2017 |
Purev E, Tian X, Aue G, Pantin J, Vo P, Shalabi R, Reger RN, Cook L, Ramos C, Cho E, Worthy T, Khuu H, Stroncek D, Young NS, Childs RW. Allogeneic transplantation using CD34(+) selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia. British Journal of Haematology. PMID 28169418 DOI: 10.1111/Bjh.14448 |
0.382 |
|
| 2017 |
Zhang W, Stevens BM, Budde EE, Forman SJ, Jordan CT, Purev E. Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome Blood. 130: 1917-1917. DOI: 10.1182/Blood.V130.Suppl_1.1917.1917 |
0.346 |
|
| 2017 |
Pollyea DA, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies Blood. 130: 181-181. DOI: 10.1182/Blood.V130.Suppl_1.181.181 |
0.336 |
|
| 2016 |
Pantin J, Purev E, Tian X, Cook L, Donohue-Jerussi T, Cho E, Reger R, Hsieh M, Khuu H, Calandra G, Geller NL, Childs RW. Effect of high-dose plerixafor on CD34+ cells mobilization in healthy stem-cell donors: results of a randomized crossover trial. Haematologica. PMID 27846612 DOI: 10.3324/Haematol.2016.147132 |
0.31 |
|
| 2016 |
Purev E, Aue G, Vo P, Kotecha R, Wilder JS, McDuffy E, Wells B, Shalabi R, Prince P, Bergerson S, Khuu HM, Stroncek D, Kurlander R, Reger RN, Flagel W, et al. Excellent Outcomes of Combined Haploidentical and Cord-Blood (Haplo-Cord) Transplantation and HLA-Matched Sibling (Matched-Sib) Donor Transplantation for High-Risk Patients with Severe Aplastic Anemia (SAA) Refractory to Immunosuppressive Therapy Blood. 128: 4689-4689. DOI: 10.1182/Blood.V128.22.4689.4689 |
0.348 |
|
| 2016 |
Vo PT, Purev E, West KA, Hochman M, McDuffee EC, Worthy T, Cook L, Ramos C, Wells B, Flegel WA, Adams S, Reger RN, Aue G, Childs RW. Complement Inhibition Using Eculizumab Overcomes Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets Blood. 128: 3840-3840. DOI: 10.1182/Blood.V128.22.3840.3840 |
0.304 |
|
| 2016 |
Carlsten M, Reger RN, Kotecha R, Purev E, Tian X, Kurlander R, Aue G, Childs RW. A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT Blood. 128: 2199-2199. DOI: 10.1182/Blood.V128.22.2199.2199 |
0.36 |
|
| 2015 |
Purev E, Srinivasan R, Aue G, Stroncek D, Khuu H, Ramos C, Cook L, Cho E, Schmitt M, Childs RW. Outpatient allogeneic hematopoietic cell transplant following alemtuzumab based reduced intensity conditioning in patients with advanced mycosis fungoides/Sezary syndrome. Journal of Clinical Oncology. 33: 7089-7089. DOI: 10.1200/Jco.2015.33.15_Suppl.7089 |
0.318 |
|
| 2015 |
Purev E, Aue G, Kotecha R, Wilder J, Khuu HM, Stroncek DF, Kurlander R, Reger RN, Flegel WA, Adams S, Cook L, Ramos C, Cho E, Childs RW. Excellent Engraftment and Long-Term Survival in Patients with Severe Aplastic Anemia (SAA) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Haplo-Identical CD34+ Cells Combined with a Single Umbilical Cord Blood Unit Blood. 126: 5516-5516. DOI: 10.1182/Blood.V126.23.5516.5516 |
0.348 |
|
| 2015 |
Purev E, Gormley N, Ramos C, Reger R, Tian X, Cho E, Reda D, Chen C, Suffredini AF, Childs RW. Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.552 |
0.303 |
|
| 2014 |
Purev E, Winkler T, Danner RL, Fahle GA, Cook L, Zerr DM, Jerome KR, Childs RW. Engraftment of donor cells with germ-line integration of HHV6 mimics HHV6 reactivation following cord blood/haplo transplantation. Blood. 124: 1198-9. PMID 25124787 DOI: 10.1182/Blood-2014-06-577684 |
0.303 |
|
| 2014 |
Purev E, Tian X, Pantin JM, Reger RN, Cook L, Ramos C, Cho E, Purvey S, Prince P, Khuu H, Stroncek D, Leitman S, Townsley DM, Young NS, Aue G, et al. Excellent Engraftment and Reduced Acute and Chronic Graft Versus Host Disease (GVHD) in ATG-Refractory Severe Aplastic Anemia (SAA) Following Transplantation of a PBSC Allograft Containing CD34+ Selected Cells Combined with Non-Mobilized Donor T-Cells Blood. 124: 3882-3882. DOI: 10.1182/Blood.V124.21.3882.3882 |
0.403 |
|
| 2014 |
Purvey S, Purev E, Tian X, Wilder J, Cook L, Ramos C, Cho E, Prince P, Leitman SF, Khuu H, Stroncek D, Reger RN, Aue G, Childs RW. High Incidence of Late, Sustained and Clinically Inconsequential Epstein Barr Virus (EBV) Reactivation Following Combined Unrelated Cord Blood and Haploidentical CD34+ Cell Transplantation Blood. 124: 1180-1180. DOI: 10.1182/Blood.V124.21.1180.1180 |
0.357 |
|
| 2013 |
Purev E, Dumitriu B, Young NS, Townsley D. Translocation (8;21) Presenting As Severe Aplastic Anemia Blood. 122: 4874-4874. DOI: 10.1182/Blood.V122.21.4874.4874 |
0.316 |
|
| 2011 |
Purev E, Soprano DR, Soprano KJ. PP2A interaction with Rb2/p130 mediates translocation of Rb2/p130 into the nucleus in all-trans retinoic acid-treated ovarian carcinoma cells. Journal of Cellular Physiology. 226: 1027-34. PMID 20857408 DOI: 10.1002/Jcp.22418 |
0.655 |
|
| 2006 |
Soprano KJ, Purev E, Vuocolo S, Soprano DR. Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene. 25: 5315-25. PMID 16936753 DOI: 10.1038/Sj.Onc.1209679 |
0.7 |
|
| 2006 |
Purev E, Giordano A, Soprano DR, Soprano KJ. Interaction of PP2A catalytic subunit with Rb2/p130 is required for all-trans retinoic acid suppression of ovarian carcinoma cell growth. Journal of Cellular Physiology. 206: 495-502. PMID 16206244 DOI: 10.1002/Jcp.20490 |
0.663 |
|
| 2006 |
Furth EE, Li J, Purev E, Solomon AC, Rogler G, Mick R, Putt M, Zhang T, Somasundaram R, Swoboda R, Herlyn D. Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. Cancer Immunology, Immunotherapy : Cii. 55: 528-37. PMID 16034560 DOI: 10.1007/S00262-005-0026-5 |
0.313 |
|
| 2004 |
Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). Journal of Immunology (Baltimore, Md. : 1950). 173: 6472-80. PMID 15528389 DOI: 10.4049/Jimmunol.173.10.6472 |
0.305 |
|
| 2004 |
Purev E, Soprano DR, Soprano KJ. Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells. Journal of Experimental & Clinical Cancer Research : Cr. 23: 309-16. PMID 15354417 |
0.591 |
|
| 2003 |
Vuocolo S, Purev E, Zhang D, Bartek J, Hansen K, Soprano DR, Soprano KJ. Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells. The Journal of Biological Chemistry. 278: 41881-9. PMID 12915404 DOI: 10.1074/Jbc.M302715200 |
0.707 |
|
| 2003 |
Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunology, Immunotherapy : Cii. 52: 145-54. PMID 12649743 DOI: 10.1007/S00262-002-0340-0 |
0.329 |
|
| 2003 |
Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine. 21: 1601-12. PMID 12639481 DOI: 10.1016/S0264-410X(02)00752-1 |
0.3 |
|
| 2001 |
Staib L, Birebent B, Somasundaram R, Purev E, Braumüller H, Leeser C, Küttner N, Li W, Zhu D, Diao J, Wunner W, Speicher D, Beger H, Song H, Herlyn D. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients International Journal of Cancer. 92: 79-87. DOI: 10.1002/1097-0215(200102)9999:9999<::Aid-Ijc1164>3.0.Co;2-J |
0.306 |
|
| Show low-probability matches. |